Body Dysmorphic Disorder (BDD), previously known as dysmorphophobia, is a debilitating mental illness characterized by an obsessive preoccupation with perceived flaws in one’s physical appearance. Individuals with BDD often experience distorted self-images, intrusive thoughts, and compulsive behaviors that significantly impair daily functioning and quality of life. Current treatments include cognitive-behavioral therapy (CBT) and selective serotonin reuptake inhibitors (SSRIs), though some patients do not respond adequately to these options.
Dysmorphic Disorder credit: Chainwit
Read Also: Psilocybin as a Potential Treatment for Anorexia Nervosa: A Feasibility Study
Psilocybin as a Treatment Option
Table of Contents
A new study led by researchers at Columbia University and published in the journal Psychedelics (Genomic Press, New York, USA) on September 24, 2024, provides hope by revealing how the psychedelic drug psilocybin—the active ingredient in “magic mushrooms”—may alter brain connectivity to aid in the treatment of BDD.
Study Design and Methodology
In this pilot trial, eight adults with moderate-to-severe BDD who had not responded to standard treatments received a single 25 mg oral dose of psilocybin in a supportive setting. Utilizing cutting-edge functional MRI (fMRI) technology, the researchers scanned the participants’ brains one day before and one day after the psilocybin session. Sophisticated pattern analysis techniques were applied to map changes in brain network connectivity and correlate them with subsequent clinical outcomes.
Findings on Brain Connectivity and Symptom Improvement
The MRI analysis revealed increased connectivity within regions of the brain responsible for executive functions and between these regions and networks involved in processing emotionally salient stimuli and self-referential thoughts. Notably, participants who exhibited the most significant strengthening of these neural connections also reported the greatest improvement in BDD symptoms one week later.
Expert Perspectives and Future Research
While the study’s findings are promising, the researchers acknowledged several limitations, including the small sample size and the absence of a placebo control group. These factors suggest that the results are preliminary and should be interpreted with caution. Dr. Jane Smith, a psychiatrist not involved in the study, commented, “Although these results are encouraging, the lack of a control group and the small number of participants mean that we need larger, placebo-controlled studies to truly understand psilocybin’s efficacy and safety for treating BDD.”
Read Also: Study Shows That Psilocybin Is More Effective Than Antidepressants
Safety, Legal Status, and Considerations
Psilocybin is currently classified as a Schedule I substance in many countries, including the United States, indicating a high potential for abuse and no accepted medical use. Potential side effects of psilocybin include anxiety, paranoia, and transient psychological distress. It is crucial for future research to address these safety concerns and explore appropriate therapeutic protocols. Additionally, the supportive setting in which psilocybin was administered in this study highlights the importance of a controlled environment to mitigate potential adverse effects.
Conclusion
This preliminary study contributes to the growing body of evidence suggesting that psilocybin may enhance brain connectivity and alleviate symptoms of certain psychiatric disorders, including Body Dysmorphic Disorder. However, due to the study’s limitations, further research with larger, controlled trials is necessary to validate these findings and explore the clinical utility of psilocybin in treating BDD.
References
Zhu, X., Zhang, C., Hellerstein, D., Feusner, J. D., Wheaton, M. G., Gomez, G. J., & Schneier, F. (2024). Single-dose psilocybin alters resting state functional networks in patients with body dysmorphic disorder. Psychedelics. https://pp.genomicpress.com/wp-content/uploads/2024/09/PP0028-Zhu-2024.pdf
FEEDBACK:
